Mohamad Mohty Selected Research

Pathologic Complete Response

10/2022	Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
1/2022	Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT.
1/2022	Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party.
1/2022	Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study.
1/2021	Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT.
1/2021	Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT.
1/2020	Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party.
1/2020	Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies.
12/2019	Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation.
11/2018	Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mohamad Mohty Research Topics

Disease

162	Leukemia 10/2022 - 08/2003
156	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2022 - 08/2003
92	Graft vs Host Disease (Graft-Versus-Host Disease) 10/2022 - 07/2003
54	Multiple Myeloma 10/2022 - 03/2008
53	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 03/2022 - 07/2002
49	Neoplasms (Cancer) 05/2022 - 07/2002
32	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 10/2003
18	Pathologic Complete Response 10/2022 - 05/2008
17	Lymphoma (Lymphomas) 10/2022 - 05/2008
17	Bronchiolitis Obliterans Syndrome 11/2021 - 11/2002
13	Residual Neoplasm 01/2022 - 02/2010
13	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2022 - 12/2012
11	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 07/2012
11	Primary Myelofibrosis (Myelosclerosis) 11/2021 - 02/2011
10	Infections 01/2021 - 11/2010
9	Disease Progression 10/2021 - 07/2011
9	Hematologic Diseases (Blood Diseases) 01/2021 - 02/2012
8	COVID-19 01/2022 - 01/2020
8	Hodgkin Disease (Hodgkin's Disease) 01/2021 - 02/2013
8	Non-Hodgkin Lymphoma (Lymphosarcoma) 12/2019 - 09/2008
6	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 01/2022 - 10/2016
6	Philadelphia Chromosome 01/2021 - 03/2015
6	Chromosome Aberrations (Chromosome Abnormalities) 01/2020 - 10/2010
5	Fibrosis (Cirrhosis) 01/2022 - 01/2011
5	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2021 - 07/2011
4	B-Cell Lymphoma (Lymphoma, B Cell) 10/2022 - 12/2019
4	Systemic Scleroderma (Systemic Sclerosis) 01/2022 - 01/2019
4	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 01/2021 - 11/2012
4	Aplastic Anemia (Anemia, Hypoplastic) 10/2019 - 10/2013
4	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2016 - 07/2002
4	Peripheral Nervous System Diseases (PNS Diseases) 03/2012 - 06/2008
3	Neutropenia 10/2021 - 01/2020
3	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 04/2021 - 11/2017
3	Bone Marrow Failure Disorders 01/2020 - 06/2012
3	Thrombocytopenia (Thrombopenia) 01/2020 - 02/2011
3	Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Congenital Disorders) 01/2020 - 01/2018
3	Cytopenia 01/2020 - 09/2013

Drug/Important Bio-Agent (IBA)

51	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2022 - 10/2013
32	Busulfan (Busulfex)FDA Link 01/2022 - 07/2003
29	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2022 - 07/2003
27	fludarabineIBA 01/2022 - 07/2003
14	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 10/2010
14	Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric 01/2022 - 01/2016
11	Bortezomib (Velcade)FDA Link 10/2021 - 03/2008
10	Melphalan (Alkeran)FDA LinkGeneric 10/2022 - 04/2015
9	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022 - 11/2010
8	Lenalidomide (CC 5013)FDA Link 01/2022 - 02/2012
8	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2022 - 01/2010
8	Chimeric Antigen ReceptorsIBA 01/2020 - 01/2019
7	Proteasome InhibitorsIBA 01/2022 - 06/2008
7	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2020 - 11/2012
6	fms-Like Tyrosine Kinase 3IBA 01/2022 - 08/2017
6	Monoclonal AntibodiesIBA 01/2022 - 09/2009
6	Thalidomide (Thalomid)FDA Link 10/2021 - 02/2010
6	Tyrosine Kinase InhibitorsIBA 01/2021 - 03/2015
6	Clofarabine (Clolar)FDA Link 08/2020 - 09/2012
6	plerixafor FDA Link 01/2019 - 11/2012
6	Imatinib Mesylate (Gleevec)FDA Link 12/2015 - 06/2004
5	defibrotideIBA 01/2022 - 10/2016
5	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2022 - 11/2008
5	Pharmaceutical PreparationsIBA 01/2022 - 01/2019
5	AntigensIBA 01/2022 - 02/2011
5	Mycophenolic Acid (Cellcept)FDA LinkGeneric 01/2022 - 03/2016
5	treosulfanIBA 01/2022 - 08/2012
5	Rituximab (Mabthera)FDA Link 09/2020 - 09/2009
5	thymoglobulin FDA Link 01/2020 - 12/2010
5	tisagenlecleucelIBA 01/2020 - 01/2019
4	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 10/2006
4	daratumumabIBA 01/2022 - 11/2019
4	Immunomodulating AgentsIBA 01/2022 - 12/2013
4	VaccinesIBA 12/2021 - 07/2002
4	SteroidsIBA 10/2021 - 09/2009
4	Etoposide (VP 16)FDA LinkGeneric 04/2021 - 01/2018
4	eculizumab FDA Link 01/2021 - 11/2012
4	Calcineurin InhibitorsIBA 01/2021 - 03/2016
4	Gemtuzumab (Mylotarg)FDA Link 12/2020 - 11/2008
4	CytokinesIBA 11/2020 - 12/2005
4	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2020 - 10/2006
4	Azacitidine (5 Azacytidine)FDA Link 01/2020 - 12/2012
4	Sorafenib (BAY 43-9006)FDA Link 03/2019 - 08/2017
3	selinexorIBA 09/2021 - 01/2019
3	Brentuximab VedotinIBA 04/2021 - 01/2018
3	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 10/2010
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2020 - 01/2011
3	ruxolitinibIBA 01/2020 - 02/2015
3	axicabtagene ciloleucelIBA 01/2020 - 12/2019

Therapy/Procedure

173	Transplantation 10/2022 - 11/2002
166	Stem Cell Transplantation 10/2022 - 11/2002
100	Hematopoietic Stem Cell Transplantation 10/2022 - 05/2008
74	Cell Transplantation 10/2022 - 10/2011
74	Therapeutics 10/2022 - 09/2005
38	Drug Therapy (Chemotherapy) 01/2022 - 08/2003
22	Haploidentical Transplantation 01/2022 - 04/2015
18	Homologous Transplantation 01/2021 - 07/2003
15	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2022 - 04/2012
9	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 10/2022 - 11/2004
9	Autologous Transplantation 06/2020 - 11/2008
8	Immunotherapy 01/2020 - 07/2002
7	Salvage Therapy 01/2019 - 10/2006
3	Splenectomy 01/2021 - 02/2011